-
#ASCO2018 . Association of genotypes, clinical scores and survival outcomes in metastatic colorectal cancer. Dr. Joan Maurel.@hospitalclinicpic.twitter.com/R3xOEeefdC
-
Professor Conroy presents landmark trial of FOLFIRINOX v Gemcitabine this afternoon
#ASCO2018. FOLFIRINOX improves survival and is a new standard of care for patients following surgery for pancreatic cancer. A remarkable result. pic.twitter.com/FHSkkd8BvD
-
Tom Gajewski discussing our data
#Asco2018 the potential of artificial intelligence to predict response to immunotherapy pic.twitter.com/qmyvRxlsk9
-
Excellent presentation on cytoreductive nephrectomy in mRCC by Arnaud Mejean - clearly shows no need to do surgery on poor or intermediate risk patients.
#ASCO2018 pic.twitter.com/MEXZD65MrK
-
Maintenance low dose chemotherapy in high-risk rhabdomyosarcoma improves overall survival.
#sarcoma#ASCO2018 pic.twitter.com/bWqqfdixs1
-
#ASCO2018 . Great company at ASCO 2018 Chicago.@OscarReigMD .@hospitalclinicpic.twitter.com/NQ4EfNlA9v
-
Assessing IO response session on the last day of
#ASCO2018. Big commitment from attendees! pic.twitter.com/71CXrdF3ox
-
-
Global disparities in cancer survival: the most powerful message of #
#ASCO2018 - we need to combine efforts on multiple fronts to tackle this. Training, education, funding, public health. pic.twitter.com/R30gYms7PF
-
An inspiring presentation of up to date evidence-based
#ASCO18 -adjusted algorithm of advanced NSCLC TODAY by@peters_solange . Great to watch, great to be part of it#LCSM#ASCO2018 pic.twitter.com/hqndZ2gKyo
-
Huntingdon et al: Cost-effectiveness analysis showing AVD+BV is not cost-effective at current price - 40-60% price reduction would be needed to reduce cost per QALY to more acceptable levels (probably not there for NHS still though).
#ASCO2018 pic.twitter.com/Cfz3yxnYLa
-
Proud to be presenting PRIMUS-001,
@precisionpanc 1st line metastatic trial in#pancreaticcancer at Trial in Progress poster session#ASCO2018@CRUKresearch@PancreaticCanUK@pancanscot@Celgenepic.twitter.com/zrxuWpkboq
-
Suboptimal Induction CT in Larynx-Hypofarynx squamous cell cancer independently linked to worse prognosis . Poster presented in
#ASCO2018 by Miguel Servet Hospital from Spain.@ttccgrouppic.twitter.com/J86FBN3l4O
-
Tonight I hugged my friend's mom & dad. My friend died of metastatic cancer last week. We all cried together as the line up behind us at the wake piled up. My husband shook her husband's hand knowing he was looking at his future. Thank you to every researcher at
#ASCO2018 -
This pathologist has loved following
#ASCO2018 from afar via Twitter! Encourage my#pathology colleagues to connect with our partners in oncology & engage in the latest cancer treatment discussions... we can learn a lot from these conversations, and can add a lot to boot! -
TAILORx study, >10,000 women recruited. Adjuvant endocrine therapy and CT-endocrine therapy similar efficacy in women with ER–positive, HER2-negative, axillary node–negative
#BRCA with a midrange recurrence score, BUT some benefit of CT was found in some women <50 yrs.#ASCO2018 pic.twitter.com/2QqtejaSKZ
-
Informative and comprehensive talk by
@ShannonWestin from@MDAndersonNews about how to incorporate tumor mutation analysis into care and clinical trials in Gyn oncology#ASCO2018 pic.twitter.com/JmzntMEEBi
-
Very interesting to note that a study which made it to the
#ASCO2018 plenary aint influencing the algorithm@peters_solange@JackWestMD@LeciaSequist@n8pennell@Jbauml@PatelOncology@TonyMok9pic.twitter.com/5ln8fYIj4N
Prikaži ovu nit -
Seems like we are looking at the new SOC for elderly not-so-fit AML. The fit ones may do even better. And aza might be a better combo than 7+3, esp. for adv risk. A robust predictive biomarker would come handy. And kudos to
@hemedoc for great#ASCO2018 tweets! https://twitter.com/hemedoc/status/1003761990190485504 …
-
Dr. Stacy Moulder about to start education series. Delivering discoveries...
#ASCO2018@MDAndersonNewspic.twitter.com/E2ffpyNgNN
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.